drugset
drugset / Trial / NCT04146181

Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma

NCT04146181 ↗

Phase 2 Unknown 103 enrolled Sinocelltech Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of SCT-I10A for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma who progressed on or after platinum-based chemotherapy

Timeline

Start
2019-10-31
Primary completion
2021-06-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Finotonlimab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma